Elicio in the News

Leveraging Lymph Nodes With Elicio’s Dr. Peter DeMuth
Chief Scientific Officer Peter DeMuth, PhD at Elicio HQ in Boston talks about how the platform works, and how it's driving rapid clinical progress for the company's robust pipeline of therapeutic vaccines in oncology. » Read more
Cancer Vaccines Push Toward Viability with New Approaches and Targets
BIOSPACE: The advances in immuno-oncology and adaptive cell therapy that began about a decade ago, however, are enabling fresh, biology-driven approaches with the potential to bring therapeutic cancer vaccines much closer to fruition. » Read more
Elicio Receives $2.8M Grant for Cancer Vaccine Development
PRECISION ONCOLOGY NEWS: Elicio Therapeutics said Tuesday that it received a $2.8 million grant from the Gastro-Intestinal Research Foundation (GIRF) in Chicago to fund research for two therapeutic cancer vaccines. » Read more
Developing Subunit Vaccines Based on an Amphiphile Platform
BIOPROCESS INTERNATIONAL: Subunit vaccines stimulate immune cells by delivering selected components of a pathogen of interest rather than the entire pathogen. Elicio Therapeutics is developing subunit vaccines that target a recipient’s lymph node to elicit a robust immune response. » Read more
Elicio Touts “Huge Potential” for Cancer Vaccine Following Preclinical Data
BIOSPACE: Immuno-oncology has grown enormously in the last decade, and the COVID-19 pandemic has accelerated our knowledge of the immune system. Elicio Therapeutics published data on the preprint server, bioRxiv, describing preclinical research on its cancer vaccine that shows a lot of promise. » Read more
Elicio inks deal with Regeneron to evaluate ELI-002 in combination with Libtay
THE PHARMA LETTER: USA-based clinical-stage biotech Elicio Therapeutics has entered into a clinical supply agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in patients with KRAS-driven tumors. » Read more
BioSpace Movers & Shakers: Singular Genomics, Marengo, Ventyx, Caribou and More
BIOSPACE: Building stronger companies requires the right leadership. This week, life sciences companies from across the globe pinpoint the Movers & Shakers who will best benefit their company. » Read more
What’s the key to being a leader in the industry?
PHARMA'S ALMANAC: Progress in Therapeutics » Read more
What important company milestone do you anticipate reaching in 2022?
PHARMA'S ALMANAC: 2022 Milestones » Read more
Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
SCRIP: High Hopes In COVID-19, Cancer, CNS, Immunology And Rare Disease » Read more
CEO to CEO: Tips for First-time Founders
BIOSPACE: We picked the brains of 10 biotech CEOs and founders to solicit their advice for first-time founders. Here’s what they told us: » Read more
Treating Cancers and Infectious Diseases by Engaging the Lymph Nodes with Bob Connelly Elicio Therapeutics
EMPOWERED PATIENT PODCAST: Bob Connelly is the CEO of Elicio Therapeutics which has figured out how to deliver immunotherapies from vaccines into the lymph nodes where they are activated to defeat cancer and infectious diseases » Read more
Undruggable no Longer
GENETIC ENGINEERING & BIOTECHNOLOGY NEWS: Cancer research has had a bit of a Cassandra problem. For decades, cancer research has had a fundamental understanding of disease biology, including key driver mutations in genes that can lead to many types of cancer. This understanding has been both a blessing and a curse » Read more
Elicio Therapeutics Begins Phase I/II Vaccine Trial in KRAS-Driven Cancers
PRECISION ONCOLOGY NEWS: Elicio Therapeutics on Wednesday said that the first patient has been dosed with ELI-002, an investigational lymph node-targeted therapeutic vaccine, by Shubham Pant, M.D. at MD Anderson as part of a Phase 1/2 (AMPLIFY-201) study evaluating its safety and efficacy as a treatment for patients with KRAS-driven tumors who have minimal residual tumor cells following surgery to remove the tumor » Read more
An In-Depth Look at Innovation on Cancer Research Day
BIOSPACE: Elicio Therapeutics is all about the lymph nodes—targeting them to treat aggressive cancers, that is. With its novel Amphiphile technology, the Cambridge, Mass.-based biotech delivers potent vaccines and immunotherapeutics directly to the “brain center” of the immune system. » Read more
Lymph node-targeted vaccine elicits COVID-19 protection in vivo
DRUG TARGET REVIEW: Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study. » Read more
Study Explores the Potential of the ELI-002 Vaccine in Patients with KRAS-Driven Tumors
TARGETED ONCOLOGY: The ELI-002 vaccine, which targets lymph nodes in patients with KRAS-driven tumors, may be a potential treatment for those with KRAS-driven tumors who have minimal residual disease following tumor resection. A current phase 1/2 dose-escalation study is currently underway to test this hypothesis. » Read more
Fierce Biotech: Chutes & Ladders
Elicio Therapeutics, developing immunotherapies that leverage its proprietary lymph node targeting technology, has named Annette Matthies, Ph.D., as chief business officer. Matthies played a key role in the initial public offering for Receptos, later picked up by Celgene for $7.2 billion, and also worked at Abbott Laboratories after its $450 million buyout of Facet Biotech, where she served in a post-acquisition integration position. Release » Read more
South Africa’s coronavirus strain upends country’s vaccination plans
LA TIMES: The coronavirus strain fueling a resurgence of COVID-19 in South Africa was not slowed down by a vaccine that officials had been counting on to protect its front-line healthcare workers, prompting the government to shelve plans for an inoculation campaign that would have begun this month. “We have decided to put a temporary […] » Read more
Appointments and advancements for Feb. 2, 2021
BIOWORLD: New hires and promotions in the biopharma industry » Read more
Next-gen Covid-19 vaccines: Elicio and its lymph node targeting approach
PHARMACEUTICAL TECHNOLOGY One next-generation Covid-19 vaccine that is about to enter clinical studies is Elicio’s ELI-005. This lymph node-targeting vaccine is composed of an adjuvant developed using the company’s Amphiphile technology and the SARS-CoV-2 virus’s spike protein RBD. Elicio head of research and development Christopher Haqq explains the differentiated mechanism of the action of this […] » Read more
ENDPOINTS: Christopher Haqq joins Elicio to hunt father’s RAS cancer
Christopher Haqq is now joining Elicio as its new R&D chief, overseeing the development of, among other things, their RAS-targeting immunotherapy. RAS mutations, which are now after 40 years of research becoming a prime target for experimental therapies, are present in about 30% of cancers, including 45% of colon cancers and nearly all pancreatic cancers. » Read more
ENDPOINTS: Elicio Therapeutics — focused on amphiphile immunotherapies — has closed its Series B with $33 million
Darrell Irvine co-founded Elicio Therapeutics — focused on amphiphile immunotherapies — has closed its Series B with $33 million. The company says that the financing will advance Elicio’s pipeline, including its amphiphile mKRAS vaccine, ELI-002 — which targets seven KRAS mutations that drive 99% of all KRAS-driven cancers. Investors for the round included Clal Biotechnology […] » Read more
BioCentury: Elicio to Advance Pancreatic, HPV Vaccines, CAR T Booster With $33M B Round
Six months after raising a $30 million series A round, Elicio has added $33 million via its B round to begin Phase I/II testing of its KRAS-driven cancer vaccine ELI-002 and advance its other immunotherapies. » Read more
BioCentury: Elicio vaccine targets oncogenic KRAS mutations
Elicio Therapeutics (Cambridge, Mass.) showed its ELI-002 vaccine generated immune responses against all common KRAS mutations, resulting in cytolytic activity against cells expressing the mutations. » Read more
Science: Boosting engineered T cells
After decades of work, researchers have finally begun to see broadly reproducible success of engineered T cells in the treatment of cancer. » Read more
ENDPOINTS: Su­per­charg­ing CAR-T with can­cer vac­cine, MIT team spot­lights some new tech un­der­pin­ning Dar­rell Irvine’s start­up
What if just amplifying CAR-T cells can do the job? Darrell Irvine and his team at MIT have some intriguing mouse data for one such tech. » Read more
Fierce Biotech: Boosting CAR-T to treat solid tumors with a vaccine
Using a vaccine that super-charges CAR-Ts at the lymph nodes, an MIT team found that they could eliminate solid tumors in 60% of mice. After that, the animals also cleared re-injected tumor cells. The findings were published in Science. » Read more
Xconomy: Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
Xconomy National— A week after the failure of Biogen’s Alzheimer’s drug aducanumab, the ripple effects are still being felt—and not just by Biogen, which lost billions of dollars in market value in a flash. We’ll kick off this week’s roundup with the aducanumab reaction, which includes plenty of thoughts about the future of the so-called […] » Read more
ENDPOINTS: Three biotechs raise $100M+ in funding for gene therapies, cancer vaccines and more
– Another day, another gene therapy developer. Prevail Therapeutics, which leapt out of stealth mode in 2017 and raised $75 million in a Series A last year for its disease-modifying approach to neurode generative diseases, has secured another $5o million in the bank. The New York-based company is run by Columbia University’s Asa Abeliovich, who […] » Read more
FierceBiotech: Elicio Therapeutics aims to sneak cancer vaccines into the lymph nodes, with $30M to launch
by Conor Hale – By targeting the body’s lymph nodes with anti-cancer vaccines, new immunotherapy developer Elicio Therapeutics aims to focus on ground zero of the body’s immune system. And to do it, the startup is getting underway with $30 million in funds, a new CEO and tech from the Massachusetts Institute of Technology. Elicio […] » Read more
BioCentury: Elicio raises $30m to target cancer vaccines to the lymph nodes
by Mary Romeo, Staff Writer – Elicio launched Wednesday with $30 million in funding and an immunotherapy strategy aimed at getting cancer vaccines into the lymph nodes, a location that orchestrates immune responses but has been hard to target directly. Elicio Therapeutics (Cambridge, Mass.) has exclusively licensed the Amphiphile platform from Darrell Irvine at the […] » Read more